What is the evidence that the MOA—tissue penetration, intracellular tropism, concentration in macrophages—of amikacin liposome inhalation suspension translates into improved clinical outcomes in patients with MAC lung disease?

What is the evidence that the MOA—tissue penetration, intracellular tropism, concentration in macrophages—of amikacin liposome inhalation suspension translates into improved clinical outcomes in patients with MAC lung disease?

CLICK HERE FOR CME CREDIT

What is the evidence that the MOA—tissue penetration, intracellular tropism, concentration in macrophages—of amikacin liposome inhalation suspension translates into improved clinical outcomes in patients with MAC lung disease? 

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | NTM-Pulmonary Infection Intelligence Zone

Presenter

Patrick Flume, MD

Patrick Flume, MD

Professor of Medicine and Pediatrics
Medical University of South Carolina
Powers-Huggins Endowed Chair for Cystic Fibrosis
University of South Carolina
Charleston, South Carolina